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Background: The AnyplexTM MTB/MDR/XDR (Seegene) detec-
tion assay is a real-time multiplex PCR that can detect
Mycobacterium tuberculosis (M.tb) and resistance to ﬁrst line drugs
(Rifampicin (RIF) and Isoniazid (INH)) and second-line drugs (Flu-
oroquinolone and injectables). Currently rapid diagnosis of drug
resistance is performed through molecular assays that have lim-
ited detection probes. Anyplex assay has a high number of probes
that are used to detect ﬁrst and second-line drugs. We compared
the performance of AnyplexTM MTB/MDR/XDR with culture and
Genotype MTBDRplus 2.0 (Hain Lifescience)for detection of M.tb
drug-resistance to ﬁrst and second-line drugs.
Methods & Materials: We retrospectively sampled 34 cul-
ture isolates and prospectively collected 51 clinical sediments.
The 34 culture strains were tested for RIF, INH, OFL (Oﬂoxacin)
and kanamycin (KAN). Of the 51 clinical sediments evaluated,
microscopy results were positive (45), negative (2) and scanty (1)
while 3 had no results. The clinical sediments were further tested
on Genotype MTBDRplus. DNA sequencing was performed on gyrA
and eis genes detected by AnyplexTM MTB/MDR/XDR assay.
Results: The concordance between culture and AnyplexTM
MTB/MDR/XDR respectively for INH, RIF, OFL and KAN was 26/26
(100%), 26/27 (96.0%), 15/16 (81.25%) and KAN (63.6%). Clinical
specimens had a concordance between Genotype MTBDRplus and
AnyplexTM MTB/MDR/XDR for INH and RIF was 4/4 (100%) and
16/17 (85.7%). The speciﬁcity for RIF and INH in clinical sediments
was 95.0% and 95.3% respectively. Analysis of discordant results of
KAN resistant samples revealedeis –C12Tmutation not detected by
AnyplexTM MTB/MDR/XDR assay.
Conclusion: AnyplexTM MTB/MDR/XDR has good overall per-
formance for detection of drug resistance in culture and clinical
sediments. High sensitivity and speciﬁcity for detection of INH
makes it an alternative method to Genotype MTBDRplus which is
based on conventional PCR.
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Background: It is only recently that the role of Type I Inter-
feron (IFN) / signalling in tuberculosis (TB) is being appreciated.
An exaggerated Type I IFN induced response is associated with TB
disease severity. However, the mechanisms by which an elevated
IFN response impacts TB disease severity are not clear. It is also
unclear whether type I IFN induced responses modulate regulatory
T (Treg) cell function in tuberculosis. The speciﬁc objectives of our
study thereforewere to ﬁrstly, validate the Type I Interferon driven
gene signature in blood of Indianpatientswith active TB and identi-
ﬁcation of unique gene signatures that help characterise latent and
active tuberculosis using RNA (transcriptome) sequencing which
has not been carried out so far. Secondly, to characterise Treg fre-
quency and function in individuals with TB and further identify
molecular signatures in whole blood that might speciﬁcally impact
Treg frequency and function.
Methods&Materials: Towards the above listed objectives, RNA
isolated from whole blood samples from healthy, latently infected,
and active TB individuals before and after treatment was subjected
to sequencing and a comprehensive list of differentially expressed
genes was obtained which was mined to obtain information about
modulation of Type I IFN genes. For the next part of the study fre-
quency of Treg cells from healthy, latent and active TB individuals
were studied by ﬂowcytometry and an assessment of Treg function
was carried out with the help of in vitro suppression assays.
Results: Data obtained from RNA transcriptome sequencing
revealed up-regulation of several Type I IFN genes like STAT2, IFIH1,
IFITM3, GBP4, TRAFD1, UBE2L6, IFI44, BATF2, OASL, ISG15 etc in active
tuberculosis. Interestingly, the expression of some of these genes
was found to diminish with treatment. A comparison of Treg fre-
quencies revealed that latently infected and individuals suffering
from active TB infection had elevated Treg cell numbers. Also, the
suppressive function of Treg cells from active TB afﬂicted individ-
uals was diminished compared to latently infected and healthy
controls.
Conclusion: We are currenty investigating if this disparity in
Treg suppressive function is a consequence of a differential Type
I IFN response. Together, these data provide novel insights to TB
pathogenesis.
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